These agents can create an immunological synapse between NK and tumor cells by simultaneously engaging other NK cell activating receptors (not CD16) with one or two tumor antigens to maximize the lysis of the tumor by NK cells. The gene discussed is FCGR3A; the disease is neoplasm.